ABSTRACT The effect of increasing intravenous doses of theophylline and enprofylline, a new xanthine derivative, on bronchial responsiveness to methacholine was studied in eight asthmatic patients. Methacholine provocations were carried out on three days before and after increasing doses of theophylline, enprofylline, and placebo, a double blind study design being used. Methacholine responsiveness was determined as the provocative concentration of methacholine causing a fall of 20% in FEV, (PC20). The patients were characterised pharmacokinetically before the main study to provide an individual dosage scheme for each patient that would provide rapid steady state plasma concentration plateaus of 5, 10, and 15 mg/l for theophylline and 1 25, 2 5, and 3-75 mg/l for enprofylline. Dose increments in the main study were given at 90 minute intervals. FEV, showed a small progressive decrease after placebo; it remained high in relation to placebo after both drugs and this effect was dose related. Methacholine PC20 values decreased after placebo; mean values were higher after theophylline and enprofylline than after placebo (maximum difference 2-0 and 1 7 doubling doses of methacholine); the effect of both drugs was dose related. Thus enprofylline and theophylline when given intravenously cause a small dose related increase in FEV1 and methacholine PC20 when compared with placebo.
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Theophylline is widely used as maintenance treatment for patients with moderately severe asthma.' In addition to causing dose related bronchodilatation,2 theophylline provides some protection against the effects of constrictor agents such as histamine and methacholine.?7 Enprofylline, a recently developed xanthine derivative, is three to five times more potent as a bronchodilator than theophylline," and might have advantages over theophylline ifcentral nervous system side effects are less.'0
In the present study increasing doses of enprofylline and theophylline were given intravenously to patients with asthma to examine the protective effect of theophylline and enprofylline on bronchoconstriction induced by inhaled methacholine and to relate this to the plasma concentrations ofthe two drugs. Before the study the pharmacokinetics of both drugs were determined for each patient so that individualised drug doses could be given and plasma concentrations held within narrow limits. The challenge tests were carried out on three days, before and after theophylline, enprofylline, and placebo. After baseline lung function measurements an inhalation provocation test with methacholine was carried out. Baseline FEV, values on the three study days had to be within 10% of the mean value for the three days, and the initial methacholine PC20 values had to be within one dose step on the three days. After the baseline measurement an infusion was given over a total period of270 minutes. An intravenous bolus dose of drug was given initially over three minutes to raise the plasma xanthine concentration to the first plateau level. The bolus dose was immediately followed by an exponentially decreasing dose by infusion during the succeeding 87 minutes. The procedure was repeated at 90 and 180 minutes'4 in an attempt to achieve the three successive concentration plateaus with increasing doses of drug. The plasma concentrations aimed for were 5 0, 10 0, and 15-0 mg/l for theophylline and 1 25, 2 50, and 3 75 mg/l for enprofylline. The drug doses needed to achieve these goals were calculated from the pharmacokinetic measurements for all the subjects and prepared by the pharmacist in individual bottles for each subject to ensure that the study was blind for both the investigators and the patients.
The inhalation provocation with methacholine was repeated on three occasions for each drug 60 minutes after the start of each infusion at an increased drug concentration. The patients were not allowed to have beverages containing xanthine during the study days.
STATISTICAL ANALYSIS
Methacholine PC20 values were log transformed. The response to theophylline and enprofylline was expressed as the difference between log PC20 on the active treatment days and the placebo days. Change in FEVy values was expressed as a percentage of the baseline value on each day. With these as dependent variables, analysis of variance was carried out with treatment and dosage step as independent variables,'5 followed by Duncan's multiple range test to establish differences between groups. Linear regression analysis was used to relate plasma xanthine concentration to change in FEV, and methacholine PC2, (baseline measurements being excluded).
Results

THEOPHYLLINE AND ENPROFYLLINE PLASMA CONCENTRATIONS
Plasma concentration remained stable during the continuous infusion period after each increment. The mean plasma concentrations (table 2) deviated little from the concentrations we aimed at (theophylline 5.3, 10-2, 15 mg/l; enprofylline 1-2, 2-4, 3.7 mg/l). Methacholine PC20 differed progressively from the values seen after placebo with increasing plasma concentrations of theophylline and enprofylline (analysis of variance, p < 0 05), a significant difference being apparent at the lowest doses (theophylline 5-0 mg/l, p < 0-01; enprofylline 1-2 mg/l: p < 0 05). Change in methacholine PC20 was related to plasma drug concentration (r = 046 for theophylline and 0 35 for enprofylline: p < 0 05 for both).
There were no significant differences between the effects of theophylline and enprofylline on FEV, or methacholine PC20 at any ofthe three dose increments. 
